Navigating Medicare Stelara Prior Authorization

Stelara: Medicare Part B vs. Part D Considerations

The primary distinction for Stelara prior authorization within Medicare involves whether the drug falls under Part B or Part D. Stelara is typically administered via subcutaneous injection or intravenous infusion. If administered in a physician's office, hospital outpatient department, or other clinical setting, it generally falls under Medicare Part B. If prescribed for self-administration and dispensed through a specialty pharmacy, it falls under Medicare Part D. This distinction dictates the specific prior authorization process, including the payer (original Medicare or Medicare Advantage for Part B; Part D plan for Part D) and the associated criteria and submission methods.

Medical Necessity Criteria for Ustekinumab (Stelara)

All Medicare plans, including Original Medicare and Medicare Advantage, require documentation of medical necessity for Stelara. These criteria are often derived from evidence-based guidelines, such as those published by MCG Health or InterQual. Common requirements include a confirmed diagnosis of an FDA-approved indication, documentation of disease severity, and often, a history of failure or contraindication to prior conventional therapies. Specific CPT codes for administration and ICD-10 codes for diagnosis must align with the payer's stated medical policies. Clinical notes must clearly support the chosen indication and severity.

Payer-Specific Policies and Delegated Reviewers

While Original Medicare (CMS) has its own coverage determinations, Medicare Advantage (MA) plans (Part C) frequently delegate prior authorization review for specialty drugs like Stelara to third-party organizations. Companies like eviCore healthcare and Carelon Medical Benefits Management (formerly AIM Specialty Health) are common delegated reviewers. Each MA plan and its delegated reviewer will have specific portals, forms, and clinical criteria that must be met. Revenue cycle teams must identify the correct submission pathway and adhere to the precise requirements of the patient's specific MA plan and its contracted review entity. This often necessitates staff training on multiple vendor platforms and policy documents.

Essential Documentation for Stelara Prior Authorization

Comprehensive and accurate documentation is paramount for successful Stelara prior authorization. Incomplete or vague submissions are a primary cause of denials. The clinical record must clearly articulate the patient's condition, treatment history, and rationale for Stelara. This includes specific details regarding disease activity and severity, as well as objective measures. Ensure all required elements are present before submission.

Key Documentation Elements for Stelara PA

• Patient demographics and insurance information.
• Clear diagnosis (ICD-10 code) matching an FDA-approved indication for Stelara.
• Provider's clinical notes detailing disease duration, severity, and impact on daily activities.
• Relevant lab results (e.g., CRP, ESR, liver function tests) and imaging reports (e.g., MRI, X-rays) supporting the diagnosis and severity.
• Documentation of prior treatment failures (medication, dosage, duration, reason for failure) or contraindications to alternative therapies.
• Patient's weight and current medication list.
• Proposed Stelara dosing regimen and route of administration.

Electronic Prior Authorization (ePA) Pathways

The shift towards electronic prior authorization (ePA) offers efficiency gains but also requires technical readiness. Many payers accept X12 278 (HIPAA) transactions, while others utilize proprietary web portals or third-party platforms like CoverMyMeds or Availity. The Da Vinci Project's Prior Authorization Support (PAS) implementation guide, leveraging SMART on FHIR, aims to standardize and automate data exchange directly from the EHR (e.g., Epic Hyperspace, Cerner PowerChart). Understanding which ePA pathway is supported by each payer and ensuring accurate data transmission is critical to reducing manual effort and turnaround times. Organizations should assess their current EMR integration capabilities for ePA.

Navigating Denials and Peer-to-Peer Reviews

Despite best efforts, Stelara prior authorizations may be denied. Operational teams must have a clear process for managing denials, including identifying the reason for denial, gathering additional requested information, and submitting appeals. A common step in the appeal process is the peer-to-peer (P2P) review. This allows the prescribing provider to discuss the medical necessity directly with the payer's medical director. Effective P2P discussions require the clinician to present a concise, evidence-based argument supported by the patient's comprehensive medical record. Documentation of the P2P discussion is critical for subsequent appeal levels.